MEDICINES WITH POTASSIUM AND MAGNESIUM IN COMPLEX PREVENTION OF COMPLICATIONS WITH PATIENTS WITH AH AND IHD


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analysis of experimental and clinical researches of medicines with potassium and magnesium application is given. The effectiveness of the given medicines for prevention of cardiovascular complications with patients with arterial hypertension and ischemic heart disease is shown.

Full Text

Restricted Access

About the authors

D. Dedov

Tver State Medical Academy; Tver Regional Clinical Cardiological Dispensary

Email: dedov d@inbox.ru
Candidate of Medicine

N. Mukailov

Hospital a structural subdivision of FSGI «1586 MCH» MD RF

I. Yevtyukhin

Hospital a structural subdivision of FSGI «1586 MCH» MD RF

References

  1. Агеев Ф., Смирнова М. и др. Применение препарата Панангин в амбулаторной практике у больных артериальной гипертонией в период летней жары // Врач. 2012; 5: 64-8.
  2. Дворянкова Е., Шевченко А. и др. Перспективы применения комбинированных лекарственных препаратов, содержащих калий и магний // Врач. -2012; 8: 49-51.
  3. Aksel'rod B., Tolstova I., Andrianova M. et al. The role of magnesium in the implementation of vascular reactions during anesthesia in cardiac surgery patients // Anesteziol. Reanimatol. 2011; 3: 813.
  4. Iezhitsa I., Spasov A. Potassium magnesium homeostasis: physiology, pathophysiology, clinical consequences of deficiency and pharmacological correction // Usp. Fiziol. Nauk. 2008; 39 (1): 23-41.
  5. Ji B., Liu J., Liu M. et al. Effect of cold blood cardioplegia enriched with potassium-magnesium aspartate during coronary artery bypass grafting // J. Cardiovasc. Surg. (Torino). 2006; 47 (6): 671-5.
  6. Manz M., Susilo R. Therapy of cardiac arrhythmias. Clinical significance of potassiumand magnesium aspartate in arrhythmias // Fortschr. Med. Orig. -2002; 120 (1): 11-5.
  7. Piper S., Kiessling A., Suttner S. et al. Prevention of atrial fibrillation after coronary artery bypass graft surgery using a potassium-magnesium-aspartate solution (Inzolen) // Thorac. Cardiovasc. Surg. 2007; 55 (7): 418-23.
  8. Pisarenko O., Serebriakova L., Tsikitishvili O. et al. Attenuation of irreversible rat heart injury by reperfusion with metabolic protectors // Biomed. Khim. 2008; 54 (6): 659-70.
  9. Pu J., Zhang C., Quan X. et al. Effects of potassium aspartate and magnesium on ventricular arrhythmia in ischemia-reperfusion rabbit heart // J. Huazhong. Univ. Sci. Technolog. Med. Sci. 2008; 28 (5): 517-9.
  10. Weigl M., Tenze G., Steinlechner B. et al. A systematic review of currently available pharmacological neuroprotective agents as a sole intervention before anticipated or induced cardiac arrest // Resuscitation. 2005; 65 (1): 21-39.
  11. Zhi Y., Huang Y., Xu B. et al. Clinical investigation of the protective effects of potassium magnesium aspartate against arrhythmia and its possible antioxidative mechanism // Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2007; 19 (11): 662-6.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2013 Russkiy Vrach Publishing House